Literature DB >> 15228128

Antibiotic resistance in the topical treatment of acne vulgaris.

James J Leyden1.   

Abstract

Topical antimicrobial agents are the first line of treatment in mild to moderate acne vulgaris. The primary pathogenic agent implicated in the development of inflammatory acne is Propionibacterium acnes. P acnes also may play a secondary role in noninflammatory acne or comedogenesis. Over the past 20 years, concern has grown about the gradual worldwide increase in the prevalence of antibiotic-resistant P acnes strains. Factors associated with the development of resistant P acnes following treatment with topical antibiotics, clinical relevance of antibiotic resistance, and strategies to reduce the incidence of P acnes resistance are discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15228128

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  7 in total

1.  Effectiveness of a polyhexanide irrigation solution on methicillin-resistant Staphylococcus aureus biofilms in a porcine wound model.

Authors:  Stephen C Davis; Andrew Harding; Joel Gil; Fernando Parajon; Jose Valdes; Michael Solis; Alex Higa
Journal:  Int Wound J       Date:  2017-03-07       Impact factor: 3.315

2.  Comparative in vitro activities of retapamulin (SB-275833) against 141 clinical isolates of Propionibacterium spp., including 117 P. acnes isolates.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 3.  Tetracyclines and bone: Unclear actions with potentially lasting effects.

Authors:  Amy J Warner; Jessica D Hathaway-Schrader; Rena Lubker; Christopher Davies; Chad M Novince
Journal:  Bone       Date:  2022-03-03       Impact factor: 4.626

4.  Fixed-Dose Combination Gel of Adapalene and Benzoyl Peroxide plus Doxycycline 100 mg versus Oral Isotretinoin for the Treatment of Severe Acne: Efficacy and Cost Analysis.

Authors:  Pete Penna; Matthew H Meckfessel; Norman Preston
Journal:  Am Health Drug Benefits       Date:  2014-01

5.  Activity of the novel macrolide BAL19403 against ribosomes from erythromycin-resistant Propionibacterium acnes.

Authors:  Jürg Dreier; Eva Amantea; Laurenz Kellenberger; Malcolm G P Page
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

Review 6.  Taurine bromamine (TauBr)--its role in immunity and new perspectives for clinical use.

Authors:  Janusz Marcinkiewicz
Journal:  J Biomed Sci       Date:  2010-08-24       Impact factor: 8.410

7.  The In vitro anti-acne activity of two unani drugs.

Authors:  Shahid Shah Chaudhary; Mohd Tariq; Roohi Zaman; Shaikh Imtiyaz
Journal:  Anc Sci Life       Date:  2013-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.